InspireMD Inc. (NASDAQ: NSPR) Commences Enrolment and Treatment of Patients in C-Guardian Study of CGuard EPS

July 26, 2021

InspireMD Inc. (NASDAQ: NSPR) dropped 6.68% after the company announced the commencement of enrollment and completed the first cases of its US registration C-Guardian study of CGuard EPS.  C-Guardian trial to enroll 315 patients  Under the care of lead investigator Chris Metzger, the first patients were implanted successfully with a CGuard EPS stent device. The patients were the first out of 315 patients the trial expected to enroll treated with…